FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021504940> ?p ?o ?g. }

• W3021504940 abstract "You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) I (PD10)1 Apr 2020PD10-07 QUALITY OF LIFE OF PROSTATE CANCER (PCA) PATIENTS WITH TESTOSTERONE DEFICIENCY SYMPTOMS (TDS) BEFORE INITIATION OF GONADOTROPIN-RELEASING HORMONE (GNRH) AGONIST THERAPY, SUBGROUP ANALYSIS OF EQUINOXE STUDY Stephane Droupy*, Marie-Helene Colson, Nathalie Pello Leprince-Ringuet, Valerie Perrot, and Aurelien Descazeaud Stephane Droupy*Stephane Droupy* More articles by this author , Marie-Helene ColsonMarie-Helene Colson More articles by this author , Nathalie Pello Leprince-RinguetNathalie Pello Leprince-Ringuet More articles by this author , Valerie PerrotValerie Perrot More articles by this author , and Aurelien DescazeaudAurelien Descazeaud More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000844.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Both PCa and TDS risk increase with age. Patients may therefore suffer from both conditions, and their quality of life (QoL) be reduced. Unexpectedly, multivariate analysis of the EQUINOXE study (NCT02630641) identified baseline TDS as a significant factor improving QoL after 6 months of GnRH agonist therapy. We therefore aim to analyze baseline parameters of this subgroup. METHODS: EQUINOXE was a French prospective, multicenter, non-interventional study. Urologists recruited partner-patient couples with PCa for whom androgen deprivation therapy (ADT) was indicated. Data were collected at inclusion and after 6 months of treatment, on QoL (WHOQOL-BREF), perception of disease (B-IPQ), symptoms of the disease (QLQ-PR25) and perception of cohesion within the patient-partner relationship (dyadic adjustment, DAS-16). TDS at baseline, determined by QLQ-PR25 “treatment related symptoms” score ≥25/100, was the main parameter identified by multivariate analysis in improvement of QoL (OR [95% CI]: 3.0 [1.46, 6.17]. Post hoc subgroup analysis was made to compare baseline parameters of patients with and without TDS. RESULTS: 487 patients were included in this analysis, 26% of whom had TDS at baseline. Symptoms were (quite a bit or very much): feeling of less masculinity (55.2%), hot flushes (41%), weight gain (40.1%) and enlarged nipples (23.1%). Patients with TDS were slightly older than those without TDS (75.3±8.3 vs 73.8±8 y.o), had significantly worse performance status (0-1-2+ in 37.0-45.7-17.3% vs 52.8-36.4-10.8%, p=0.0153) and suffered more frequently from recurrent PCa (35.7% vs 24.7%, p=0.0175). Symptoms other than urinary and sexual (but including asthenia) were more frequent (p=0.0126). All dimensions of WHOQOL-BREF were rated significantly worse: QoL (54.8±24.3 vs 64.3±21.5, p<0.0001), satisfaction with health (44.6±25.4 vs 52.8±23.9, p=0.0014), physical (51.6±18.1 vs 63.2±17.3, p<0.0001), psychological (59.2±17.6 vs 66.9±14.6, p<0.0001), social (51.7±17.2 vs 60.4±14.5, p<0.0001), and environment (59.5±17.4 vs 63.5±15.2, p=0.0262). Total score of illness (B-IPQ) was worse: 42.2±8.2 vs 39.1±9.4, p=0.0040. Cohesion in the couple (DAS score) was worse: 98.6±22.3 vs 107.3±20.9, p=0.0006. CONCLUSIONS: Patients with TDS experienced at baseline a worse cohesion of the couple and a lower QoL than patients without TDS but benefited relatively more from ADT in term of QoL. Source of Funding: IPSEN PHARMA © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e248-e248 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Stephane Droupy* More articles by this author Marie-Helene Colson More articles by this author Nathalie Pello Leprince-Ringuet More articles by this author Valerie Perrot More articles by this author Aurelien Descazeaud More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W3021504940 created "2020-05-13" @default.
• W3021504940 creator A5020394771 @default.
• W3021504940 creator A5033163047 @default.
• W3021504940 creator A5071893202 @default.
• W3021504940 creator A5086435294 @default.
• W3021504940 creator A5088337969 @default.
• W3021504940 date "2020-04-01" @default.
• W3021504940 modified "2023-09-27" @default.
• W3021504940 title "PD10-07 QUALITY OF LIFE OF PROSTATE CANCER (PCA) PATIENTS WITH TESTOSTERONE DEFICIENCY SYMPTOMS (TDS) BEFORE INITIATION OF GONADOTROPIN-RELEASING HORMONE (GNRH) AGONIST THERAPY, SUBGROUP ANALYSIS OF EQUINOXE STUDY" @default.
• W3021504940 doi "https://doi.org/10.1097/ju.0000000000000844.07" @default.
• W3021504940 hasPublicationYear "2020" @default.
• W3021504940 type Work @default.
• W3021504940 sameAs 3021504940 @default.
• W3021504940 citedByCount "0" @default.
• W3021504940 crossrefType "journal-article" @default.
• W3021504940 hasAuthorship W3021504940A5020394771 @default.
• W3021504940 hasAuthorship W3021504940A5033163047 @default.
• W3021504940 hasAuthorship W3021504940A5071893202 @default.
• W3021504940 hasAuthorship W3021504940A5086435294 @default.
• W3021504940 hasAuthorship W3021504940A5088337969 @default.
• W3021504940 hasBestOaLocation W30215049401 @default.
• W3021504940 hasConcept C121608353 @default.
• W3021504940 hasConcept C126322002 @default.
• W3021504940 hasConcept C143998085 @default.
• W3021504940 hasConcept C159110408 @default.
• W3021504940 hasConcept C170493617 @default.
• W3021504940 hasConcept C187960798 @default.
• W3021504940 hasConcept C2777899217 @default.
• W3021504940 hasConcept C2778938600 @default.
• W3021504940 hasConcept C2779279991 @default.
• W3021504940 hasConcept C2779951463 @default.
• W3021504940 hasConcept C2780192828 @default.
• W3021504940 hasConcept C29456083 @default.
• W3021504940 hasConcept C71924100 @default.
• W3021504940 hasConcept C95190672 @default.
• W3021504940 hasConceptScore W3021504940C121608353 @default.
• W3021504940 hasConceptScore W3021504940C126322002 @default.
• W3021504940 hasConceptScore W3021504940C143998085 @default.
• W3021504940 hasConceptScore W3021504940C159110408 @default.
• W3021504940 hasConceptScore W3021504940C170493617 @default.
• W3021504940 hasConceptScore W3021504940C187960798 @default.
• W3021504940 hasConceptScore W3021504940C2777899217 @default.
• W3021504940 hasConceptScore W3021504940C2778938600 @default.
• W3021504940 hasConceptScore W3021504940C2779279991 @default.
• W3021504940 hasConceptScore W3021504940C2779951463 @default.
• W3021504940 hasConceptScore W3021504940C2780192828 @default.
• W3021504940 hasConceptScore W3021504940C29456083 @default.
• W3021504940 hasConceptScore W3021504940C71924100 @default.
• W3021504940 hasConceptScore W3021504940C95190672 @default.
• W3021504940 hasIssue "Supplement 4" @default.
• W3021504940 hasLocation W30215049401 @default.
• W3021504940 hasOpenAccess W3021504940 @default.
• W3021504940 hasPrimaryLocation W30215049401 @default.
• W3021504940 hasRelatedWork W2012724875 @default.
• W3021504940 hasRelatedWork W2522846761 @default.
• W3021504940 hasRelatedWork W2996796527 @default.
• W3021504940 hasRelatedWork W3126918870 @default.
• W3021504940 hasRelatedWork W3173857525 @default.
• W3021504940 hasRelatedWork W3192241040 @default.
• W3021504940 hasRelatedWork W4226305114 @default.
• W3021504940 hasRelatedWork W4232178292 @default.
• W3021504940 hasRelatedWork W4292397309 @default.
• W3021504940 hasRelatedWork W4309472912 @default.
• W3021504940 hasVolume "203" @default.
• W3021504940 isParatext "false" @default.
• W3021504940 isRetracted "false" @default.
• W3021504940 magId "3021504940" @default.
• W3021504940 workType "article" @default.